Sonoma Pharmaceuticals (SNOA, Financial) has secured registration for its hypochlorous acid-based acne treatment products with the Medicines & Healthcare products Regulatory Agency in the United Kingdom. This regulatory approval paves the way for the distribution of these products through a significant health and beauty retailer and pharmacy chain.
The acne treatments, leveraging the therapeutic properties of hypochlorous acid, are set to be available in over 1,200 stores across the UK. This expansion marks a strategic step for Sonoma Pharmaceuticals in broadening its market presence within the international skincare sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Sonoma Pharmaceuticals Inc (SNOA, Financial) is $17.00 with a high estimate of $17.00 and a low estimate of $17.00. The average target implies an upside of 629.61% from the current price of $2.33. More detailed estimate data can be found on the Sonoma Pharmaceuticals Inc (SNOA) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Sonoma Pharmaceuticals Inc's (SNOA, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
